Rx for FDA Inaction: Competition
Executive SummaryThe FDA won't reform itself because it is a monopoly, argues Peter Barton Hutt. His solution: competition: if either the European Medicines Evaluation Agency or the UK's Medicines Control Agency approves a drug, the FDA would have 90 days to veto a sponsor's application for approval--any veto having to be accompanied by a specific clinical rationale.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.